Physician profile
David C Ringel
NPI 1457889859
$1,953.52
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223 · 2022: $1,579 · 2023: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $151.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $443.68 | 2022 | |
| Abbvie INC. | $323.71 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Amgen INC. | $275.01 | 2022-2023 | Repatha, Otezla |
| Lilly USA, LLC | $180.08 | 2021-2022 | |
| Novo Nordisk INC | $144.89 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $89.67 | 2021-2022 | |
| Sanofi Pasteur INC. | $67.83 | 2022 | |
| Eisai INC. | $51.51 | 2021-2022 | |
| Glaxosmithkline, LLC. | $47.68 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $46.43 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $41.37 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.63 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.94 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $24.44 | 2022 | |
| Exeltis, USA INC. | $24.21 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $24.20 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $19.18 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.51 | 2021 | |
| Lundbeck LLC | $18.18 | 2022 | |
| Lucid Diagnostics INC. | $16.21 | 2022 | |
| Collegium Pharmaceutical, INC. | $14.97 | 2022 | |
| Currax Pharmaceuticals LLC | $14.75 | 2022 | |
| Cranial Technologies, INC | $13.44 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ringel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.